Overview: Ganciclovir is used to prevent or treat infection caused by a virus called cytomegalovirus (CMV). It prevents the virus from multiplying in the body by disrupting its ability to create DNA.

I would like the opinion of the panel on the use and clinical utility of serum ganciclovir levels when treating symptomatic cytomegalovirus (CMV) disease. Particularly in cases where CMV viremia and ...

Learn everything you need to know about Ganciclovir-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

On September 15, 2003, the US Food and Drug Administration changed the indications for valganciclovir (Valcyte) to include prevention of CMV disease in kidney, pancreas, and heart transplant patients.

Alejo Erice, Nuria Borrell, Wuyi Li, Wesley J. Miller and Henry H. Balfour Jr. Ganciclovir susceptibilities and UL97 sequences were analyzed in 20 cytomegalovirus (CMV) isolates recovered from 15 bone ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Valganciclovir is an orally administered prodrug that is rapidly hydrolyzed to ganciclovir. We compared the effects of oral valganciclovir with those of intravenous ganciclovir as induction therapy ...

18 May 2004, Basel, Switzerland - Data presented at the American Transplant Congress (ATC) annual meeting show that the gold standard CMV antiviral ganciclovir (Valcyte/Cymevene) has been proven to ...

Details concerning the Ganciclovir medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

There has been no controlled study of antiviral therapy in patients with HHV-6 infections. Salivary gland epithelium supports HHV-6 replication and infectious HHV-6 is frequently detectable in saliva.

An Institutional Biosafety Committee–, Institutional Review Board–, Recombinant DNA Advisory Committee–, and US Food and Drug Administration–approved phase I study used intrapatient dose escalation of ...